Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053319 · ClinicalTrials.gov registry record · Phase 1
SGLT2i, Pioglitazone, and Ketone Production in T2D
A Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT07053319 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07053319, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Conditions Studied
Interventions
- DRUG Empagliflozin 25 MG plus Pioglitazone placebo
- DRUG Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
- DRUG Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- DRUG Pioglitazone placebo + Empagliflozin placebo
Study Locations (1)
Texas
- Texas Diabetes Institute/UH - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053319
The ClinicalTrials.gov registry entry for NCT07053319 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which Empagliflozin 25 MG plus Pioglitazone placebo is the first listed.
NCT07053319 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07053319 about?
NCT07053319 is a clinical study titled "SGLT2i, Pioglitazone, and Ketone Production in T2D". To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
What is the current status of trial NCT07053319?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2026-07-20. Estimated completion is 2027-06-30.
What conditions does trial NCT07053319 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07053319?
The interventions under investigation include: Empagliflozin 25 MG plus Pioglitazone placebo (DRUG), Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo (DRUG), Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) (DRUG), Pioglitazone placebo + Empagliflozin placebo (DRUG).
Who is sponsoring clinical trial NCT07053319?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053319 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
-
SGLTi, Hepatic Glucose Production and Ketogenesis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.